← Oncology Approval Tracker

FDA DECISION ·

Brukinsa

zanubrutinib · BeiGene

Accelerated approvalNew or expanded indicationMarginal zone lymphoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with relapsed or refractory marginal zone lymphoma after at least one anti-CD20-based regimen.

LAMPGEN ANALYSIS

Why it matters

The accelerated decision expands BTK inhibition to previously treated marginal zone lymphoma.

What research teams should watch

Document histologic subtype and anti-CD20 exposure and track duration of response separately from initial response.

PRIMARY RECORDS

Sources